Liu Yingru, Perez Julianny, Hammer Laura A, Gallagher Heather C, De Jesus Magdia, Egilmez Nejat K, Russell Michael W
TherapyX, Inc., Buffalo, New York, USA.
Department of Biomedical Sciences, University at Albany, Albany, New York, USA.
mSphere. 2018 Jan 31;3(1). doi: 10.1128/mSphere.00421-17. eCollection 2018 Jan-Feb.
It has previously been shown that genital tract infection with in mice does not induce a state of protective immunity against reinfection but instead suppresses the development of adaptive immune responses against dependent on transforming growth factor beta (TGF-β) and interleukin 10 (IL-10). Intravaginal administration during gonococcal infection of IL-12 encapsulated in biodegradable microspheres (IL-12/ms) reverses the immunosuppression and promotes the production of gamma interferon (IFN-γ) and of specific antibodies in serum and genital secretions and accelerates clearance of the infection. In this study, microspheres were shown to remain largely within the genital tract lumen and to release IL-12 over the course of 4 days. Antigonococcal IgA and IgG antibodies induced by IL-12/ms treatment reacted with antigenically different strains of and led to resistance to reinfection with heterologous and homologous strains. Immune resistance to reinfection persisted for at least 6 months after clearance of the primary infection. Experiments performed with immunodeficient strains of mice lacking either IFN-γ or B cells demonstrated that both IFN-γ and B cells were necessary for the IL-12-induced generation of immune responses to and the resulting accelerated clearance of the infection. It is therefore concluded that intravaginally administered IL-12/ms achieves its effect by the sustained release of IL-12 that promotes Th1-driven adaptive immune responses, including the production of specific antigonococcal antibodies that cross-react with multiple strains of . IL-12-enhanced immunity to can be recalled against reinfection after prolonged intervals and is dependent upon both IFN-γ and antibody production by B cells. Genital infection with (gonorrhea) is a significant cause of reproductive tract morbidity in women, leading to pelvic inflammatory disease, tubal factor infertility, and increased risk for ectopic pregnancy. WHO estimates that 78 million new infections occur annually worldwide. In the United States, >350,000 cases are reported annually, but the true incidence is probably >800,000 cases/year. Increasing resistance to currently available antibiotics raises concern that gonorrhea might become untreatable. Infection does not induce a state of immune protection against reinfection. Previous studies have shown that suppresses the development of adaptive immune responses by mechanisms dependent on the regulatory cytokines TGF-β and IL-10. This study shows that intravaginal treatment of gonococcal infection in female mice with microencapsulated IL-12 induces persisting anamnestic immunity against reinfection with , even of antigenically diverse strains, dependent on T-cell production of IFN-γ and B-cell production of antibodies.
先前的研究表明,小鼠生殖道感染淋病奈瑟菌不会诱导产生针对再次感染的保护性免疫状态,反而会抑制依赖转化生长因子β(TGF-β)和白细胞介素10(IL-10)的针对淋病奈瑟菌的适应性免疫反应的发展。在淋病奈瑟菌感染期间,经阴道给予包裹在可生物降解微球中的白细胞介素12(IL-12/微球)可逆转免疫抑制,促进血清和生殖分泌物中γ干扰素(IFN-γ)和特异性抗体的产生,并加速感染的清除。在本研究中,微球在很大程度上保留在生殖道腔内,并在4天的时间内释放IL-12。IL-12/微球治疗诱导产生的抗淋病奈瑟菌IgA和IgG抗体与抗原性不同的淋病奈瑟菌菌株发生反应,并导致对异源和同源菌株再次感染产生抗性。在原发性感染清除后,对再次感染的免疫抗性持续至少6个月。对缺乏IFN-γ或B细胞的免疫缺陷小鼠品系进行的实验表明,IFN-γ和B细胞对于IL-12诱导的针对淋病奈瑟菌的免疫反应的产生以及由此加速的感染清除都是必需的。因此得出结论,经阴道给予IL-12/微球通过持续释放IL-12发挥作用,IL-12促进Th1驱动的适应性免疫反应,包括产生与多种淋病奈瑟菌菌株发生交叉反应的特异性抗淋病奈瑟菌抗体。IL-12增强的针对淋病奈瑟菌的免疫力在长时间间隔后可被唤起以抵抗再次感染,并且依赖于IFN-γ的产生和B细胞产生抗体。女性的淋病奈瑟菌生殖道感染(淋病)是生殖道发病的一个重要原因,可导致盆腔炎、输卵管因素不孕症以及异位妊娠风险增加。世界卫生组织估计全球每年有7800万新感染病例。在美国,每年报告超过35万例病例,但实际发病率可能超过80万例/年。对现有抗生素的耐药性不断增加引发了人们对淋病可能变得无法治疗的担忧。感染不会诱导针对再次感染的免疫保护状态。先前的研究表明,淋病奈瑟菌通过依赖调节性细胞因子TGF-β和IL-10的机制抑制适应性免疫反应的发展。本研究表明,用微囊化IL-12对雌性小鼠的淋病奈瑟菌感染进行经阴道治疗可诱导对淋病奈瑟菌再次感染的持久回忆性免疫,即使是对抗原性不同的菌株,这依赖于T细胞产生IFN-γ和B细胞产生抗体。